SCHEMBL5677684

SCHEMBL5677684

Cc1ccccc1C(=O)OC[C@H]1O[C@@H](O)[C@](C)(O)[C@@H]1OC(=O)c1ccccc1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 3/20 0.37
ADRB2 P07550 2/20 0.37
ADRB1 P08588 2/20 0.37
ADRB3 P13945 2/20 0.37
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
BCHE P06276 1/20 0.36
MAPT P10636 3/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677495 1.00 L3MBTL1 (0.39) L3MBTL1KMT2AMEN1TSHRADRB2
SCHEMBL5679566 1.00 L3MBTL1 (0.39) L3MBTL1KMT2AMEN1TSHRADRB2
SCHEMBL1837289 0.83 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1TDP1MAPT
SCHEMBL1837286 0.83 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1TDP1MAPT
SCHEMBL5707588 0.82 L3MBTL1 (0.36) L3MBTL1KMT2AMEN1TSHRADRB2
SCHEMBL5707620 0.82 L3MBTL1 (0.36) L3MBTL1KMT2AMEN1TSHRADRB2
SCHEMBL3996036 0.80 HPGD (0.54) KMT2AALDH1A1TDP1MAPTHPGD
SCHEMBL13772424 0.80 HPGD (0.54) KMT2AALDH1A1TDP1MAPTHPGD
SCHEMBL3996032 0.80 HPGD (0.54) KMT2AALDH1A1TDP1MAPTHPGD
SCHEMBL5680406 0.79 ADRB2 (0.37) L3MBTL1KMT2AMEN1TSHRADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631573-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO SpA (IT) 2006-03-08 EP disclosed
US-6891036-B2 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2005-05-10 US disclosed
WO-2004069851-A1 PROCESS FOR THE PREPARATION OF RIBOFURANOSE DERIVATIVES INALCO S.P.A. (IT) 2004-08-19 WO disclosed
US-20040158059-A1 Process for the preparation of ribofuranose derivatives INALCO S.P.A. (IT) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158059-A1 Process for the preparation of ribofuranose derivatives RNGTT, RPIA, MRM1 L3MBTL1 3137/4885KMT2A 1720/4885MEN1 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.